louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01237782: Efficacy of a Propolis-based Denture Cleanser
Official title: Efficacy of a Propolis Solution for Cleaning Complete Dentures: a Randomized Crossover Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Plaque
Denture Stomatitis
Oral Candidiasis
Oral Hygiene
Keywords: Candida
Complete Denture
Dental Plaque Index
Denture Bases
Denture Cleansers
Edentulous Mouth
Mutans Streptococci
Oral Health
Propolis
Streptococcus mutans
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2010-11-10
Enrollment: 30
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess if a propolis solution is able to remove plaque and kill microbes from complete dentures. The investigators will compare the results of the propolis-based denture cleanser with those obtained with an inactive solution.


Eligibility criteria: Inclusion Criteria:

* Good general health
* Patients requesting new complete dentures
* Regular wearing of the same maxillary and mandibular complete dentures for at least one year
* Both denture bases and artificial teeth should be composed by acrylic resin

Exclusion Criteria:

* Unsatisfactory complete dentures in use (i.e. with poor fitting, relining or fractures)
* Pathologic changes in the oral cavity

Primary outcomes:
measure: Denture plaque coverage area (%)
timeFrame: At the same day of the intervention, up to 1 hour following denture soaking
Secondary outcomes:
measure: mutans streptococci counts (CFU)
timeFrame: At the same day of the intervention, up to 1 hour following denture soaking
measure: Candida spp. counts (CFU)
timeFrame: At the same day of the intervention, up to 1 hour following denture soaking
Other outcomes:
Locations:
city: Ribeirão Preto
country: Brazil
facility: Ribeirão Preto Dental School
state: São Paulo
Study officials:
affiliation: University of Sao Paulo
name: Raphael F de Souza, DDS, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05811182: Vitreous Hyper Reflective Dots in Association With Pseudophakic Cystoid Macular Edema
Official title: Prospective Analysis of the Correlation Between Hyperreflective Dots in the Vitreous Body and the Appearance of a Pseudophakic Cystoid Macular Edema
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystoid Macular Edema Following Cataract Surgery
Vitreous Hyperreflective Dots
Keywords: VHD
phacoemulsification
CME
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2023-04-13
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing cataract surgery using the manual anterior continuous curvilinear capsulorhexis phacoemulsification technique for the removal of the crystalline lens and subsequent implantation of a monofocal hydrophobic acrylic intraocular lens in the capsular bag

Brief summary: The aim of this study is to assess the association between vitreous hyper-reflective dots (VHD) and the macular thickness changes following uneventful phacoemulsification. In this prospective study the investigators performed optical coherence tomography (OCT) imaging in patients undergoing cataract surgery preoperatively and postoperatively after 1 week, 1 month and 3 months and analyzed the OCTs for VHDs. The investigators then measured the macular thickness in patients with VHDs and without VHDs and correlated the macular thickness with the number of VHDs.


Eligibility criteria: Inclusion Criteria:

* patients undergoing cataract surgery
* minimum age 18 years
* phacoemulsification technique
* subsequent implantation of a monofocal hydrophobic acrylic intraocular lens

Exclusion Criteria:

* intraoperative complications including capsule rupture with or without anterior vitrectomy
* iris bites
* previous interventions including vitrectomy
* glaucoma surgery
* exudative or dry age-related macular degeneration
* presence of diabetes
* history or presence of retinal vein occlusion or uveitis
* epiretinal glioses

Primary outcomes:
measure: vitreous hyperreflective dots
timeFrame: preoperatively until 3 months postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University of Graz
state: Styria
Study officials:
References:
Clinical trial NCT05570682: Manually Controlled Infusion Vs Target Controlled Infusion for StrokeThrombectomy
Official title: Manually Controlled Infusion Vs Target Controlled Infusion: an Hemodynamic Alterations in StrokeThrombectomy Evaluation (HASTE); a Multi-center Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Stroke, Ischemic
Stroke/Brain Attack
Anesthesia
Hemodynamic Instability
Lead sponsor: University of Padova
Sponsor class: OTHER
First posted: 2022-10-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this randomized controlled trial is to compare manual general anesthesia induction to general anesthesia induction guided by target controlled infusion system in cerebral ischemic stroke

The main questions it aims to answer are:

* Does target controlled infusion has a more favorauble hemodynamic profile than manual general anesthesia induction?
* Do patients receiving general anesthesia with target controlled infusion system have a more favourable outcome? Participants will receive general anesthesia induction with a target controlled infusion system and will be compared to patients receiving manual general anesthesia induction.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years;
* Anterior Cerebral Circulation Stroke
* Patient eligible for mechanical trombectomy
* mRS ≤ 2;
* Fasting patients (\>6 h solid, \>2 hours liquids)
* Glashow Coma Scale more than seven.

Exclusion criteria

* Patient in general anesthesia at hospital arrival
* Associated hemorrhagic stroke

Primary outcomes:
measure: Number of patients with Intraprocedural Hypotension
timeFrame: Up to three hours
Secondary outcomes:
measure: Change from baseline in National Institutes of Health Stroke Scale at 24 hours after acute ischemic stroke
timeFrame: 24 hours after acute ischemic stroke
measure: Change from baseline in National Institutes of Health Stroke Scale at 7 days after acute ischemic stroke
timeFrame: 7 days after acute ischemic stroke
measure: Evaluation of Modified Rankin Scale at 3 months after acute ischemic stroke
timeFrame: 3 months after acute ischemic stroke
measure: Percentage of patients alive at 3 months after acute ischemic stroke
timeFrame: 3 months after acute ischemic stroke
measure: Difference in modified treatment in cerebral infarction (mTICI) score
timeFrame: 24 hours after ischemic stroke
measure: Difference in time from door to groin
timeFrame: Up to 6 hours
measure: Difference in time from groin to reperfusion
timeFrame: Up to 6 hours
measure: Difference in Intensive Care Unit/Stroke Unit stay
timeFrame: Up to 30 days
Other outcomes:
Locations:
city: Padova
country: Italy
facility: University Hospital of Padova
state: Veneto
Study officials:
References:
Clinical trial NCT00954382: Trends in Intellectual Development in Down Syndrome
Official title: Trends in Intellectual Development, and Diverging Verbal and Non-verbal Abilities in the Down Syndrome Phenotype
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Down Syndrome
Keywords: Down syndrome
IQ
mental age
neuropsychological function
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2009-08-07
Enrollment: 60
Sex: ALL
Minimum age (years): 3
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Down syndrome

Brief summary: Previous foreign studies revealed that the IQ in Down syndrome (DS) declines with age, but not any investigation of domestic data in Taiwan was available. Individuals with DS are characterized by limited verbal development, and in this article, authors look into the diverging verbal-nonverbal abilities in the DS phenotype.

Detailed description: The present study investigated this by analysis the test results of development /intelligence scales. To compare initial cross-sectional data with longitudinal follow-up, about 12 people with DS were included.

Eligibility criteria: Inclusion Criteria:

* Down syndrome with psychological test results

Exclusion Criteria:

* Comorbidity of severe Autism or visual/auditory impairment

Primary outcomes:
measure: IQ
timeFrame: 2001-2010
Secondary outcomes:
measure: mental age
timeFrame: 2001-2010
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: NTUH
Study officials:
affiliation: NTUH
name: Wuh-Liang Hwu, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01509482: Insulin Resistance in Idiopathic Oligospermia and Azoospermia
Official title: Insulin Resistance : a New Diagnosis of the Pathogenesis of Idiopathic Oligozoospermia and Non Obstructive Azoospermia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin Resistance
Oligospermia
Azoospermia
Keywords: insulin resistance
unexplained azoospermia
unexplained oligospermia
Lead sponsor: The Egyptian IVF-ET Center
Sponsor class: OTHER
First posted: 2012-01-13
Enrollment: 100
Sex: MALE
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Insulin resistance in men can be the underlying major factor in reproductive abnormalities ( chronic hypospermatogenesis ) as well as metabolic abnormalities similar to polycystic ovarian syndrome ( PCOS ) in women.

Detailed description: During the past decade IR has been recognized as a major contributor to the pathogenesis of chronic anovulation, hyperandrogenism and metabolic abnormalities associated with PCOS . Theoretically IR in men may result in a similar reproductive abnormalities ( chronic hypospermatogenesis ) as well as other metabolic abnormalities similar to what happens in PCOS in women .

Eligibility criteria: Inclusion Criteria:

* sperm count less than 10 million per milliliter
* non-obstructive azoospermia

Exclusion Criteria:

* high FSH ( \> 10 mIU/ ml )
* high prolactin ( \> 36 mIU/ml )
* abnormal karyotype
* AZF

Primary outcomes:
measure: serum insulin
timeFrame: one month
Secondary outcomes:
measure: Fasting Glucose
timeFrame: one month
measure: cholesterol
timeFrame: one month
measure: high density lipoprotein ( HDL)
timeFrame: one month
measure: Low density lipoprotein ( LDL )
timeFrame: one month
measure: testosterone
timeFrame: one month
measure: Triglycerides
timeFrame: One month
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: The Egyptian IVF-ET center
Study officials:
affiliation: The Egyptian IVF-ET Center
name: Ragaa Mansour, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00222482: Depakote ER in Borderline Personality Disorder
Official title: A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Borderline Personality Disorder
Keywords: Borderline Personality Disorder
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: Abbott
name: Schulz, S. Charles, M.D.
First posted: 2005-09-22
Enrollment: 15
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.


Eligibility criteria: Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

-

Primary outcomes:
measure: Symptom Checklist 90
Secondary outcomes:
measure: Barratt Impulsivity Scale
Other outcomes:
Locations:
Study officials:
affiliation: Department of Psychiatry, University of Minnesota Medical School
name: Sellamnn C Schulz, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999 Nov 15;46(10):1429-35. doi: 10.1016/s0006-3223(99)00128-6.
citation: Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, Vollm BA, Mattivi JT, Faltinsen E, Todorovac A, Jorgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.
Clinical trial NCT06663982: Connective Tissue Graft and Leucocyte - Platelet Rich Fibrin in Alveolar Ridge Preservation
Official title: Periosteal Inhibition Technique With Connective Tissue Graft and Leucocyte- Platelet Rich Fibrin in Alveolar Ridge Preservation: a Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Alveolar Socket Preservation
Lead sponsor: G. d'Annunzio University
Sponsor class: OTHER
First posted: 2024-10-29
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of our randomized controlled clinical trial is to evaluate radiographic bone dimensional changes and soft tissue healing and thickness after teeth extraction and the implementation of alveolar ridge preservation (RAP) procedures that will involve the application of L-PRF inside the socket in association with a connective tissue graft (CTG) used as a barrier with the periosteal inhibition technique (PI). The present experimental treatment (test group) will be compared with an active comparator (control group) which will involve the insertion of L-PRF alone inside the socket.


Eligibility criteria: * Age \> 18 years old;
* General good health (ASA I-II);
* Adequate oral hygiene (Full Mouth Plaque Score ≤ 20%, Full Mouth Bleeding Score ≤ 20%);
* Presence of one or more hopeless teeth requiring extraction.

Primary outcomes:
measure: Horizontal Bone Crest
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02479282: Effect of Natural Cesarean Section on Breastfeeding
Official title: Effect of Natural Cesarean Section in Comparison to Traditional Cesarean Section on Maternal and Fetal Recovery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Natural Cesarean Section
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2015-06-24
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Effect of natural cesarean section in comparison to traditional cesarean section on maternal and fetal recovery.


Eligibility criteria: Inclusion Criteria:

1. primigravida or para one section
2. full term
3. cephalic
4. single baby
5. average weight
6. spinal anathesia

Exclusion Criteria:

1. High risk pregnancy.
2. Women with known or suspected fetal malformation.
3. Women with uterine malformations.
4. Breech or transverse lie.
5. Emergency caesarean section.
6. Previous two or more caesarean section

Primary outcomes:
measure: time to start breastfeeding
timeFrame: 3 hrs
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01564082: Comparison of Early Endotracheal Tube Insertion With GlideScope Use
Official title: Comparison of Early Endotracheal Tube Insertion With GlideScope Use
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endotracheal Intubation
Keywords: endotracheal intubation
GlideScope
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients presenting for elective surgery will be randomized to having the breathing tube inserted partly into the throat prior to GlideScope insertion, or having it inserted fully after GlideScope insertion.

Detailed description: Patients presenting for elective surgery requiring orotracheal intubation will be randomized to having the Early Endotracheal Tube (ETT) inserted into the pharynx prior to GlideScope insertion and then having the ETT advanced under GlideScope guidance into the trachea, or, being intubated in the standard fashion with the GlideScope being inserted first and having the ETT then advanced via the pharynx into the trachea. The primary outcome is time to intubation.

Eligibility criteria: Inclusion Criteria:

1. Any adult patient booked for elective surgery requiring orotracheal intubation.
2. Any operator who has performed ≥ 20 GlideScope intubations.

Exclusion Criteria:

1. Any patient in whom the use of the GlideScope is contraindicated in the opinion of the attending anesthesiologist.
2. Any patient with cervical spine abnormalities.
3. Any patients with known or probable difficult airways.
4. Any patient requiring rapid sequence induction.

Primary outcomes:
measure: Time to Intubation
timeFrame: Day 1
Secondary outcomes:
measure: Ease of intubation
timeFrame: Day 1
measure: Number of intubation attempts
timeFrame: Day 1
measure: Use of external laryngeal pressure
timeFrame: Day 1
measure: Sore throat
timeFrame: Day 3
Other outcomes:
Locations:
city: London
country: Canada
facility: St. Joseph's Health Care
state: Ontario
city: London
country: Canada
facility: London Health Sciences Center
state: Ontario
Study officials:
affiliation: LHRI
name: Timothy P Turkstra, MD, M. Eng.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004982: Combination Iron Chelation Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Iron Overload
Thalassemia
Keywords: chelation therapy
combination chemotherapy
iron poisoning
thalassemia
chelating agent
deferoxamine
drug screening /evaluation
therapy evaluation
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2000-03-14
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.


Eligibility criteria: Inclusion Criteria:

* Iron overload

Exclusion Criteria:

* Overt cardiac disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Cornell University Medical College
state: New York
Study officials:
References:
Clinical trial NCT03346382: Emergency Medical Services and Epilepsy in Switzerland
Official title: Treatment of Epilepsy in Children and Adults in the Emergency Medical Services of the City of Zurich, Switzerland - Midazolam Versus Diazepam - A Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: Epilepsy
Emergency medical services
Lead sponsor: Balgrist University Hospital
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 584
Sex: ALL
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: retrospective collected data from the emergency medical system "Schutz \& Rettung Zürich", Zurich, Switzerland, over an 18 months period from 01. June 2013 till 31. December 2014 - all calls for epileptic seizures

Brief summary: Retrospective data analysis, all emergency medical services of the city of Zurich interventions due to epileptic convulsions during June 2013 and December 2014 have been analyzed regarding the type of drug used, its application mode and the application mode based success. Furthermore, children versus adults were compared. Continuous variables were summarized as mean ± standard deviation (SD) and also presented as median \[minimum; maximum\]. Groups were compared using the independent samples t-test. P-values \< 0.05 are considered significant.


Eligibility criteria: Inclusion Criteria:

* emergency calls for epileptic seizures received by the emergency medical system of Zurich,Switzerland,
* the use of midazolam or diazepam or no drug used.

Exclusion Criteria:

* the use of any other first line drug to stop seizures than the two mentioned above e.g. thiopental

Primary outcomes:
measure: Which drug (Midazolam versus Diazepam) better stops epileptic seizures in the pre-clinical setting
timeFrame: follow up up to 1 year
Secondary outcomes:
measure: Does the way of application of the drugs (Midazolam versus Diazepam) used in pre-clinical epileptic seizures influence the outcome
timeFrame: follow up up to 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Balgrist University Hospital
name: Oliver M Theusinger, MD
role: STUDY_CHAIR
References: